ArticleTrials2026
Cross-training digital therapeutics for pediatric ADHD: study protocol for a randomized controlled trial.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06369714 (Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAttention-deficit/hyperactivity disorder (ADHD) in children can result in academic and occupational failure, poor socialization, and an increased risk of accidental injuries. Digital therapeutics (DTx) leverage computers and smartphones to provide game-based treatments targeting ADHD's cognitive and behavioral aspects. Although the evidence base for DTx in ADHD is expanding, most DTx focus on a single mechanism without leveraging potential synergies between them. This study aims to evaluate the effectiveness of a cross-training DTx for children aged 6-12 with ADHD.
methodsThe DTx study is a multicenter, open-label, randomized controlled trial that employs a cross-training approach integrating neurofeedback and executive function training. A total of 210 participants will be randomly assigned to one of three groups: the medication group (MED), the DTx group (DTX), or the combination group (COM). DTX will receive home‑based digital training, MED will receive methylphenidate, and COM will receive both. The primary outcome is change in Swanson, Nolan, and Pelham Rating Scale (SNAP‑IV) total score from baseline to 8 weeks post-randomization. Non‑inferiority will be tested between DTX and MED with a non-inferiority margin of Δ = 4 points; superiority between COM and MED will be defined as the lower bound of the two‑sided 95% confidence interval for the difference being greater than 0. DISCUSSION: The clinical trial protocol presented here outlines a randomized controlled trial that evaluates DTx utilizing cross-training approach. The aim of this trial is to assess the efficacy and acceptability of the cross-training DTx for children aged 6 to 12 years with ADHD. The primary outcome is the degree of improvement in the core symptoms of ADHD (measured by SNAP‑IV). Additionally, we will evaluate compliance and potential side effects associated with the DTx. The results of this study may provide an optional non-pharmacological intervention/supplementary treatment option for children with ADHD.
trial registrationNCT06369714. Registered on 17 April 2024. https://clinicaltrials.gov/study/NCT06369714 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.